Suppr超能文献

采用液相色谱-质谱联用技术测定人血浆和尿液中的非索非那定。

Determination of fexofenadine in human plasma and urine by liquid chromatography-mass spectrometry.

作者信息

Hofmann Ute, Seiler Monika, Drescher Siegfried, Fromm Martin F

机构信息

Dr. Margarete Fischer-Bosch-Institut für Klinische Pharmakologie, Stuttgart, Germany.

出版信息

J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Jan 25;766(2):227-33. doi: 10.1016/s0378-4347(01)00468-6.

Abstract

A sensitive method was developed to determine fexofenadine in human plasma and urine by HPLC-electrospray mass spectrometry with MDL 026042 as internal standard. Extraction was carried out on C18 solid-phase extraction cartridges. The mobile phases used for HPLC were: (A) 12 mM ammonium acetate in water and (B) acetonitrile. Chromatographic separation was achieved on a LUNA CN column (10 cm x 2.0 mm I.D., particle size 3 microm) using a linear gradient from 40% B to 60% B in 10 min. The mass spectrometer was operated in the selected ion monitoring mode using the respective MH+ ions, m/z 502.3 for fexofenadine and m/z 530.3 for the internal standard. The limit of quantification achieved with this method was 0.5 ng/ml in plasma and 1.0 ng in 50 microl of urine. The method described was successfully applied to the determination of fexofenadine in human plasma and urine in pharmacokinetic studies.

摘要

建立了一种灵敏的方法,以MDL 026042为内标,采用高效液相色谱-电喷雾质谱法测定人血浆和尿液中的非索非那定。在C18固相萃取柱上进行萃取。高效液相色谱所用的流动相为:(A)水中12 mM乙酸铵和(B)乙腈。在LUNA CN柱(10 cm×2.0 mm内径,粒径3微米)上进行色谱分离,采用10分钟内从40% B到60% B的线性梯度。质谱仪在选择离子监测模式下运行,使用各自的MH+离子,非索非那定为m/z 502.3,内标为m/z 530.3。该方法在血浆中的定量限为0.5 ng/ml,在50微升尿液中的定量限为1.0 ng。所描述的方法成功应用于药代动力学研究中测定人血浆和尿液中的非索非那定。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验